In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Isis Remain A Platform Company?

Executive Summary

With a bulging pipeline, piles of cash, and Big Pharma partners knocking on its doors, Isis believes it is under no pressure to sell its own products. But several factors – including outside pressures and issues intrinsic to Isis’ platform model – are coming into play that may hasten its evolution into an integrated biopharma. And for the first time, Isis management appears open to the possibility.

You may also be interested in...



Isis Builds On Platform Strategy With Fourth Biogen Tie-Up

The antisense company has made it clear that it will not pursue commercialization of its own drugs, but intends to partner out all of its assets, while still retaining the most advantageous economics. Its fourth agreement with Biogen Idec, a strategic collaboration, is the most extensive and lucrative to date with the partner.

Building A Fully Integrated Biotech Company: What It Takes

A typical mature biotech company evolves over four discrete stages – from the initial discovery stage through the preclinical and early clinical stage, then to the late clinical trials and commercial build-out – before it becomes a fully integrated biotech company. The final transition is a make-or-break scenario for any biotech company, and high-quality marketed products alone don’t guarantee a successful transformation.

Theravance To Split Into A Royalty Play and An R&D Company

With a pair of PDUFA dates this year, Theravance is thinking ahead how to pass potential royalties to investors while continuing to fund its pipeline. The biopharma said it would separate into two public companies: a royalty play to return cash to shareholders and an R&D pipeline story.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

IV004088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel